Oxford BioMedica, the leading gene therapy company, announces today that they have received a Notice of Allowance from the US Patent Office for a Patent containing broad claims covering modifications to lentiviral vectors that improve safety and efficacy.

Oxford BioMedica owns an extensive portfolio of broad patents and patent applications covering many aspects of the composition of matter and use of gene delivery systems based on lentiviral vectors. This patent estate underpins the Company’s neurotherapy pipeline of five products and is the subject of recent commercial deals with a number of companies including Merck and Biogen Idec.
Read the full press release